The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of FOLFOX versus XELOX as adjuvant chemotherapy in patients with early-stage colorectal adenocarcinoma.
Dimitrios G. Pectasides
No relevant relationships to disclose
George Papaxoinis
No relevant relationships to disclose
Ioannis Xanthakis
No relevant relationships to disclose
George Kouvatseas
No relevant relationships to disclose
Vassiliki Kotoula
No relevant relationships to disclose
Nikolaos Xiros
No relevant relationships to disclose
Epaminondas Samantas
No relevant relationships to disclose
Pavlos Papakostas
No relevant relationships to disclose
George Klouvas
No relevant relationships to disclose
Ioannis I. Varthalitis
No relevant relationships to disclose
George E. Pentheroudakis
No relevant relationships to disclose
George Fountzilas
No relevant relationships to disclose
Dimitris Bafaloukos
No relevant relationships to disclose